African Trypanosomiasis (Sleeping Sickness)

1. Comprehensive Introduction & Overview

African Trypanosomiasis, clinically referred to as Human African Trypanosomiasis (HAT) or "Sleeping Sickness," is a lethal, vector-borne parasitic disease endemic to sub-Saharan Africa. It is caused by protozoan parasites of the genus Trypanosoma brucei. The disease is transmitted to humans through the bite of an infected tsetse fly (Glossina species), which inhabits rural areas of sub-Saharan Africa.

Without prompt medical intervention, HAT is almost universally fatal. The disease progresses through two distinct clinical stages: the hemolymphatic stage (Stage 1) and the meningoencephalitic stage (Stage 2), where the parasite crosses the blood-brain barrier, leading to the characteristic neurological deterioration that gives the condition its name.

There are two primary subspecies of the parasite that cause distinct clinical forms:
* Trypanosoma brucei gambiense (T.b. gambiense): Responsible for >95% of reported cases; found in West and Central Africa. It causes a chronic, slow-progressing infection.
* Trypanosoma brucei rhodesiense (T.b. rhodesiense): Found in East and Southern Africa; causes an acute, rapidly progressing infection.

2. Deep-Dive: Etiology and Pathophysiology

Etiology

The transmission cycle involves the tsetse fly acting as both the vector and the intermediate host. When a tsetse fly bites an infected host, it ingests the trypomastigotes. These undergo transformation and multiplication in the fly's midgut and salivary glands before becoming infective metacyclic trypomastigotes. Upon a subsequent bite, these are injected into the human subcutaneous tissue, transforming into bloodstream trypomastigotes.

Pathophysiology

The pathology of HAT is defined by the parasite’s ability to evade the host immune system through antigenic variation. The parasite expresses a dense coat of Variable Surface Glycoproteins (VSG). As the host produces antibodies against these glycoproteins, the parasite periodically switches its VSG coat, staying one step ahead of the adaptive immune response.

The inflammatory response in the central nervous system (CNS) results in perivascular cuffing, microglial activation, and eventually, profound cerebral edema and demyelination.

3. Extensive Clinical Indications and Presentation

Clinical Staging

The differentiation between Stage 1 and Stage 2 is the most critical aspect of clinical management, as it dictates the therapeutic approach and drug selection.

Stage 1: Hemolymphatic Presentation

• Chancre: A painful, indurated skin lesion at the site of the tsetse bite (more common in T.b. rhodesiense).
• Winterbottom’s Sign: Posterior cervical lymphadenopathy—a classic hallmark of T.b. gambiense.
• Systemic Symptoms: Undulating fevers, malaise, arthralgia, and headaches.
• Dermatological: Transient erythematous rashes.

Stage 2: Meningoencephalitic Presentation

• Sleep Cycle Disturbance: The hallmark "sleeping" aspect; patients exhibit daytime somnolence and nocturnal insomnia.
• Neurological: Tremors, ataxia, slurred speech, and motor weakness.
• Psychiatric: Confusion, aggression, personality changes, and apathy.
• Endocrine: Amenorrhea, impotence, and weight loss.

4. Diagnostic Protocols and Laboratory Testing

Diagnostic accuracy is paramount because medications for HAT are highly toxic.

Key Diagnostic Tests

1. Serological Screening: The Card Agglutination Test for Trypanosomiasis (CATT) is used for field surveys in T.b. gambiense endemic areas.
2. Parasitological Confirmation: Direct visualization of the parasite in blood, lymph node aspirates, or cerebrospinal fluid (CSF).
   • Microscopy: Giemsa-stained thin and thick blood smears.
   • Concentration Techniques: Hematocrit Centrifugation Technique (HCT) or the Mini-Anion Exchange Centrifugation Technique (mAECT).
3. Lumbar Puncture (Staging): Mandatory once the parasite is detected.
   • CSF Analysis: White blood cell (WBC) count >5 cells/µL or the presence of trypanosomes indicates Stage 2.

Differential Diagnosis

The nonspecific nature of early symptoms often leads to misdiagnosis. Clinicians must rule out:
* Malaria
* Tuberculosis
* HIV/AIDS
* Typhoid fever
* Relapsing fever (borreliosis)

5. Risks, Side Effects, and Contraindications

Treatment for HAT is notoriously difficult due to the toxicity of the drugs required to penetrate the CNS.

Therapeutic Options

• Pentamidine: First-line for Stage 1 T.b. gambiense. Side effects include hypotension, hypoglycemia, and nephrotoxicity.
• Suramin: First-line for Stage 1 T.b. rhodesiense. Side effects include proteinuria and allergic reactions.
• Melarsoprol: An arsenic-based drug for Stage 2. It is highly toxic; the most severe side effect is reactive encephalopathy, which is fatal in 5% of cases.
• Nifurtimox-Eflornithine Combination Therapy (NECT): Currently the standard for Stage 2 T.b. gambiense. It is safer and more effective than melarsoprol.

Contraindications

• Pregnancy: Many anti-trypanosomal drugs are teratogenic.
• Severe Renal/Hepatic Impairment: Requires dose adjustment or alternative therapy to avoid systemic collapse.

6. Long-Term Prognosis

The prognosis depends entirely on the stage at which the patient is treated.
* Early Stage Treatment: Excellent prognosis with a near 100% cure rate and minimal long-term neurological sequelae.
* Late Stage Treatment: Varies significantly based on the degree of pre-existing CNS damage. While the parasite is usually cleared, some patients may suffer from permanent cognitive deficits, motor impairment, or endocrine dysfunction.
* Post-Treatment Follow-up: Patients must be monitored for at least 24 months with repeated CSF examinations to confirm the absence of relapse.

7. Frequently Asked Questions (FAQ)

1. Is Sleeping Sickness contagious?

No. It is a vector-borne disease. It cannot be transmitted from person to person through casual contact. It is transmitted only via the bite of an infected tsetse fly.

2. Can I get HAT in the United States or Europe?

Only through travel to endemic regions in sub-Saharan Africa. It is not endemic in North America or Europe.

3. What is the difference between Stage 1 and Stage 2?

Stage 1 is limited to the blood and lymph system. Stage 2 is critical because the parasite has crossed into the brain, causing neurological symptoms.

4. Why is it called "Sleeping Sickness"?

The name originates from the severe disruption of the circadian rhythm in Stage 2, where the patient experiences overwhelming daytime sleepiness followed by nocturnal restlessness.

5. Is there a vaccine for HAT?

Currently, no vaccine exists. Prevention relies on vector control (traps, insecticides) and personal protection (wearing long-sleeved, neutral-colored clothing).

6. Can T.b. gambiense be treated with T.b. rhodesiense drugs?

Generally, no. The drug regimens are highly specific to the subspecies and the clinical stage of the disease.

7. How long does it take for symptoms to appear?

For T.b. rhodesiense, symptoms can appear within days or weeks. For T.b. gambiense, the infection can remain asymptomatic for months or even years.

8. What is the "Winterbottom’s Sign"?

It is the swelling of lymph nodes at the back of the neck. It is a common clinical sign used by medical professionals to screen for the disease.

9. What is the most common side effect of HAT treatment?

The treatments are highly toxic. Common side effects include nausea, vomiting, dizziness, and, in the case of melarsoprol, a high risk of fatal reactive encephalopathy.

10. Does a negative blood test guarantee I don't have it?

Not necessarily. Because the parasite levels in the blood can be low, multiple tests or concentration techniques (like mAECT) may be required to confirm a diagnosis.

8. Summary Table of Clinical Management

Disclaimer: This document is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. In the event of suspected exposure to African Trypanosomiasis, seek immediate specialized care at a tropical medicine center.